Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients

Prognosis of hepatocellular carcinoma (HCC) remains unsatisfying due to a lack of early detecting methods. Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) has been proved to be an efficient biomarker for HCC. However, the predicting efficacy of PIVKA-II has barely been reported. In...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-10, Vol.6 (1), p.35050-35050, Article 35050
Main Authors: Yu, Rentao, Xiang, Xiaomei, Tan, Zhaoxia, Zhou, Yi, Wang, Haoliang, Deng, Guohong
Format: Article
Language:English
Subjects:
631/67/1504/1610/4029
631/67/2322
Adult
Aged
alpha-Fetoproteins - metabolism
Biomarkers - blood
Biomarkers, Tumor - blood
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - metabolism
Case studies
Case-Control Studies
Early Detection of Cancer - methods
Female
Hepatitis
Hepatocellular carcinoma
Humanities and Social Sciences
Humans
Liver cancer
Liver Neoplasms - diagnosis
Liver Neoplasms - metabolism
Male
Middle Aged
multidisciplinary
Prognosis
Protein Precursors - blood
Prothrombin
Retrospective Studies
Science
Sensitivity and Specificity
Vitamin K
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prognosis of hepatocellular carcinoma (HCC) remains unsatisfying due to a lack of early detecting methods. Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) has been proved to be an efficient biomarker for HCC. However, the predicting efficacy of PIVKA-II has barely been reported. In the Hepatitis Biobank of Southwest Hospital (HBS) cohort at Southwest Hospital, we did a two-stage nested case-control study. Totally, 45 HCC cases versus 138 matched controls were enrolled to compare levels of α-fetoprotein (AFP) and PIVKA-II in sequential sera at −12, −9, −6, −3 and 0 months before imaging diagnosis. Levels of both PIVKA-II and AFP in HCC cases elevated significantly at all time points compared with controls. In validation stage, the sensitivity and specificity of PIVKA-II at baseline were 58.3% and 92.6%, and AFP were 75.0% and 91.7%. AFP-/PIVKA-II+ patients covered 27.4%, 29.4% and 19.6% at M-12, M-6 and M-0, respectively, while AFP+/PIVKA-II- patients covered 25.5%, 19.6% and 17.7%, respectively. Both PIVKA-II and AFP have the potential for HCC prediction, while PIVKA-II has a better positive rate than AFP before diagnosis.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep35050